Heparin sodium API Supplier describes the pharmacological effects of Heparin sodium: It inhibits prothrombin kinase formation. Antithrombin iii (AT-PARA) is a serine protease inhibitor that inactivates clotting factors with serine protease activity (e.g., clotting factors A, T A, F, T A).
Heparin sodium API Supplier: Heparin inhibits prothrombin kinase formation
The drug binds to the δ Amino-Lysine residue of AT- ⅲ to form a complex that accelerates the inactivation of coagulation factors and thus inhibits prothrombin kinase formation. And counteracts the action of prothrombin kinase, which has been developed. It interferes with the action of thrombin. The combination of low dose of this product with AT- ⅲ makes at-choline reaction site (arginine residue) more easily combine with thrombin active center (serine residue), forming a stable thrombin - antithrombin complex, thus inactivating thrombin and inhibiting the conversion of fibrinogen to fibrin. It interferes with thrombin's activation of coagulation factor ⅹ ⅲ, affects the formation of cross-linked fibrin, and prevents thrombin from activating coagulation factor normally. Prevent platelet aggregation and destruction.
The drug inhibits platelet adhesion and aggregation, thereby preventing platelet disintegration and releasing platelet factor 3 and serotonin. The anticoagulant action of the drug is related to the strongly negatively charged sulfate in the molecule. When the sulfate group is hydrolyzed or neutralized by strongly positively charged protamine, it immediately loses its anticoagulant activity.